Congress doubles funding for sickle cell disease research and treatment
H.R. 1796 — Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 · Filed by John James (R-MI) · 6 cosponsors · Introduced Mar 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill reauthorizes and expands a federal sickle cell disease research and treatment program. It broadens the program's scope to explicitly include prevention and treatment of complications (not just the disease itself), allows grants in addition to contracts, and nearly doubles annual funding from $4.46 million to $8.21 million for fiscal years 2025–2029. The bill benefits patients with sickle cell disease and related blood disorders by increasing research capacity and treatment options.
Why we flagged it
The bill is a straightforward reauthorization and expansion of an existing federal research and treatment program for a specific disease. It increases funding, broadens program scope, and adds administrative flexibility — all standard public-health legislative mechanics with no hidden riders or private carve-outs.
What the text implies
- Shift from 'prevention and treatment' to 'treatment and prevention of complications' may subtly de-emphasize primary prevention (e.g., genetic counseling, carrier screening) in favor of clinical management — though the bill does not explicitly restrict prevention work.
- Addition of grant authority alongside contracts may increase administrative burden on NIH/CDC but also enable smaller research institutions and community health centers to participate, potentially improving equity in research access.
The full analysis lists 3 implications of this text.
Who stands to gain
National Institutes of Health (NIH) — receives expanded grant-making authority and increased appropr; Centers for Disease Control and Prevention (CDC) — likely receives surveillance and prevention fundi; Academic medical centers and research institutions — eligible for grants and contracts